Advancements in CTC Enumeration for Breast Cancer Treatment
The secondary analysis of the PACE trial highlights the promising role of Circulating Tumor Cells (CTCs) in guiding treatment strategies for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. This is particularly relevant for cases that progressed after treatments involving aromatase inhibitors and CDK4/6 inhibitors. CTC enumeration is emerging as a viable standalone predictive biomarker, functioning independently of clinical risk factors and circulating tumor DNA.
Significant Findings from the PACE Trial Analysis
Menarini Silicon Biosystems, notable for its innovations in cell-based liquid biopsy technologies, recently published the CTC biomarker analysis results from the PACE trial in a prestigious journal. This multicenter phase II clinical study, which began in 2017, sought to determine whether CTC count could yield valuable prognostic and predictive insights for HR+/HER2- metastatic breast cancer patients who exhibited disease progression after first-line treatment.
In the study, a total of 203 patients were randomly assigned to receive either endocrine monotherapy or combination therapies, such as a doublet consisting of endocrine therapy plus a CDK4/6 inhibitor, or a triplet therapy that included an immune checkpoint inhibitor. Depending on their CTC levels, these patients were categorized into two prognostic groups: those with fewer than 5 CTCs per 7.5 mL of blood, indicative of indolent disease, and those with 5 or more CTCs, reflecting aggressive disease. While the overall treatment groups did not show substantial differences in progression-free survival, patients classified with aggressive disease (5 or more CTCs) demonstrated a notable reduction in progression risk with combination therapies. Specifically, there was a 57% reduction in the progression risk for patients undergoing doublet therapy, while triplet therapy resulted in an impressive 74% reduction compared to monotherapy.
Expert Insights on the Implications of CTC Enumeration
Dr. Lorenzo Gerratana, an Associate Professor at the University of Udine and a leading researcher in the PACE analysis, emphasized the importance of CTC enumeration. He stated that the analysis reveals how this metric can help identify HR+/HER2- metastatic breast cancer patients who are more likely to respond positively to intensified therapeutic interventions after their disease progresses following initial treatments. In contrast, those with indolent disease did not experience significant benefits from treatment intensification compared to monotherapy.
As the biological mechanisms underlying resistance to CDK4/6 inhibitors remain largely unexplored, identifying reliable biomarkers becomes essential to inform treatment pathways post-disease progression.
Consistency with Previous Research and Future Directions
The findings from the PACE trial resonate with the results from the STIC trial, which indicated that treatment pathways based on CTC counts could yield different outcomes than standard physician choices. When discrepancies arose, they either resulted in enhanced survival rates or permitted treatment de-escalation without adverse effects on survival.
Fabio Piazzalunga's Commitment to Enhanced Patient Management
Fabio Piazzalunga, President of Menarini Silicon Biosystems, acknowledged the consistently significant contributions of CELLSEARCH CTC enumeration in managing patients with metastatic breast cancer. He expressed commitment to ongoing support for healthcare professionals, enabling informed decisions to either escalate treatment to manage disease progression or de-intensify therapy to better preserve patient quality of life. The CELLSEARCH test is available for In Vitro Diagnostic Use across Europe and China, as well as in the U.S. via their certified laboratory in Huntingdon Valley, Pa.
About CELLSEARCH and MSB
CELLSEARCH is recognized as the only CE-marked, clinically validated blood test cleared by the FDA for CTC enumeration, assisting physicians in managing patients with various metastatic cancers including breast, prostate, and colorectal cancers. It is important to note that while CELLSEARCH is clinically validated, the CTC Kit is not cleared for directing specific treatment decisions, and the clinical data referenced here pertain to investigational uses beyond its approved indications.
Menarini Silicon Biosystems, a subsidiary of the Menarini Group based in Bologna, Italy, and Huntingdon Valley, Pa., is a leading player in pharmaceuticals and diagnostics with a dedicated workforce across numerous countries.
Frequently Asked Questions
What is the significance of CTC enumeration in treatment decisions?
CTC enumeration helps identify patients who may benefit from more aggressive therapy, potentially improving their clinical outcomes after treatment progression.
What were the main findings of the PACE trial analysis?
The PACE trial found that patients with aggressive disease benefitted significantly more from combination therapies compared to monotherapy based on their CTC levels.
How does CELLSEARCH assist physicians?
CELLSEARCH facilitates the management of patients by providing accurate CTC counts to inform treatment strategies for metastatic cancers.
Is the CELLSEARCH test approved for specific treatment guidance?
No, the CELLSEARCH CTC Kit is not cleared for guiding specific treatment decisions but assists in understanding patient prognosis.
Who are the key players in Menarini Silicon Biosystems?
Menarini Silicon Biosystems is led by professionals like Fabio Piazzalunga, focused on enhancing treatment pathways through innovative diagnostic solutions.
